{"ATC Code":"N06AB06","Abbreviation":[],"Adverse Effects":"SSRIs, considered a newer class of antidepressants, are better tolerated than tricyclic antidepressants or monoamine oxidase inhibitors. The primary side effects of sertraline include syncope, lightheadedness, diarrhea, nausea, sweating, dizziness, xerostomia, confusion, hallucinations, tremor, somnolence, impotence, a disorder of ejaculation, fatigue, rhinitis, and female sexual disorder.","Aliases":["Sertralina","Sertralinum","Cp 51974","cis-(+)-sertraline","(1S,4S)-sertraline","(1S-cis)-1,2,3,4-Tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine","Altruline","1-Naphthalenamine, 1,2,3,4-tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-, (1S-cis)-","Besitran","Apo Sertraline","Gen Sertraline","Novo Sertraline","ratio Sertraline","Rhoxal sertraline","1-Naphthalenamine,1,2,3,4-tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-, (1S-cis)-","N06AB06","642-001-4","79617-95-1","C17H17Cl2N","TBA-2010_Sertraline_1","(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-tetralin-1-amine","cis-sertraline","(R,R)-Sertraline","Mls001401398","1-Naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-, (1S,4S)-"],"Biological Half-Life":"The elimination half-life of sertraline is approximately 26 hours. One reference mentions an elimination half-life ranging from 22-36 hours.","Boiling Point":"416.3±45.0 °C","CAS":"79617-96-2","ChEBI":"CHEBI:9123","ChEMBL":"CHEMBL809","ChemicalClasses":["α-alkylbenzylamine"],"Chirality":"absolute","Classes":["Serotonin reuptake inhibitor"],"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Antidepressive Agents; Serotonin Uptake Inhibitors","Drug Indication":"Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD). Common off-label uses for sertraline include the prevention of post stroke depression, generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.","Drug Warnings":"Side effects of Sertraline include: mild agitation, minimal sedation, moderately severe GI effects, \u0026 moderately severe sexual effects. /from table/","Erowid Experience Reports":null,"Esters":[],"European Community (EC) Number":"616-708-3","FDA Pharmacological Classification":"QUC7NX6WMB","Formating":[],"HMDB ID":"HMDB0005010","HeavyAtomCount":20,"Human Drugs":"Antidepressants -\u003e Selective serotonin reuptake inhibitors (SSRI)","IUPACName":"(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine","InChI":"InChI=1S/C17H17Cl2N/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11/h2-6,8,10,12,17,20H,7,9H2,1H3/t12-,17-/m0/s1","InChIKey":"VGKDLMBJGBXTGI-SJCJKPOMSA-N","Interactions":"Examples of drug interactions with serotonin-reuptake inhibitors include potentiation of agents metabolized prominently by CYP1A2 (e.g. beta-adrenergic receptor antagonists, caffeine, several antipsychotic agents, \u0026 most tricyclic antidepressants); CYP2C9 (carbamazepine); CYP2C19 (barbiturates, imipramine, propranolol, phenyltoin); CYP2D6 (beta-adrenergic receptor antagonists, some antipsychotics, many antidepressants); CYP3A3/4 (benzodiazepines, carbamazepine, many antidepressants, \u0026 several antibiotics). /Serotonin-reuptake inhibitors/","MeSH Pharmacological Classification":"Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.","Melting Point":"245-246","MolecularFormula":"C\u003csub\u003e17\u003c/sub\u003eH\u003csub\u003e17\u003c/sub\u003eCl\u003csub\u003e2\u003c/sub\u003eN","MolecularWeight":"306.2 g/mol","Opticalactivity":"( + )","Pharmacodynamics":"Sertraline improves or relieves the symptoms of depression, OCD, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, and premenstrual dysphoric disorder via the inhibition of serotonin reuptake. Clinical studies have shown that it improves cognition in depressed patients. It has less sedative, anticholinergic, and cardiovascular effects than the tricyclic antidepressant drugs because it does not exert significant anticholinergic, antihistamine, or adrenergic (alpha1, alpha2, beta) blocking activity. The onset of action and beneficial effects are usually noticed after 4-6 weeks, for reasons that are not fully understood and currently under investigation.","Physical Description":"Solid","PubChemId":68617,"Record Description":["LiverTox|CNS|Antidepressant|SSRI"],"RefCount":3,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Sertraline","Name":"Sertraline","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB01104","Name":"Sertraline","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/68617","Name":"Sertraline","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL809","Name":"Sertraline","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9123","Name":"Sertraline","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=79617-96-2","Name":"Sertraline","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0005010","Name":"Sertraline","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07246","Name":"Sertraline","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/QUC7NX6WMB","Name":"Sertraline","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID6023577","Name":"Sertraline","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 68617, Sertraline. Accessed August 16, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/68617\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/68617\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Sertraline. UNII: QUC7NX6WMB. Global Substance Registration System. Accessed August 16, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/QUC7NX6WMB\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/QUC7NX6WMB\u003c/a\u003e"],"SMILES":"CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl","SaltData":[{"AcidCount":1,"Amine":"Sertraline","AmineCount":1,"Formula":"Cl","Name":"hydrochloride","Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 77.804 118.435\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#1ff01f\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h78v119H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"M53.833 1.038 43.789 6.839\" class=\"bond\"/\u003e\u003cpath fill=\"#000\" stroke=\"none\" d=\"M40.287 23.9h.701l1.306-11.391h-3.316z\" class=\"bond\"/\u003e\u003cpath d=\"m40.637 23.9 13.199 7.616M53.836 31.516l.005 15.239M53.841 46.755 40.647 54.38M40.647 54.38l-13.203-7.612\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m14.246 54.388 13.198-7.62M14.247 51.572l10.759-6.211\"/\u003e\u003c/g\u003e\u003cpath d=\"M14.246 54.388 1.043 46.76\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m1.038 31.511.005 15.249M3.477 32.919l.004 12.433\"/\u003e\u003c/g\u003e\u003cpath d=\"m1.038 31.511 13.198-7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m27.44 31.52-13.204-7.629M25.002 32.927l-10.766-6.22\"/\u003e\u003c/g\u003e\u003cpath d=\"M40.637 23.9 27.44 31.52M27.444 46.768 27.44 31.52\" class=\"bond\"/\u003e\u003cpath fill=\"#000\" stroke=\"none\" d=\"M40.997 54.38h-.7l-1.891 16.54 2.249-1.3 2.25 1.298z\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m40.655 69.62-13.2 7.633M40.657 72.436 29.893 78.66\"/\u003e\u003c/g\u003e\u003cpath d=\"m27.455 77.253.001 15.248\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m27.456 92.501 13.201 7.616M29.894 91.093l10.761 6.208\"/\u003e\u003c/g\u003e\u003cpath d=\"m40.657 100.117 13.2-7.634\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m53.857 92.483-.001-15.248M51.418 91.077V78.643\"/\u003e\u003c/g\u003e\u003cpath d=\"m40.655 69.62 13.201 7.615M40.657 100.117l.006 11.3M27.456 92.501 15.772 99.25\" class=\"bond\"/\u003e\u003cg fill=\"#3050f8\" stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M42.576 11.109h-.72l-2.619-4.066h-.03l.03.596q.024.357.024.732v2.738h-.566V6.21h.714l2.608 4.054h.03l-.018-.327-.024-.477q-.006-.262-.006-.482V6.21h.577zM38.133 11.109h-.619V8.823h-2.512v2.286h-.613V6.21h.613v2.072h2.512V6.21h.619z\"/\u003e\u003c/g\u003e\u003cpath stroke=\"none\" d=\"M41.159 113.38q-.786 0-1.239.53-.452.524-.452 1.447 0 .91.417 1.446.422.53 1.268.53.321 0 .607-.054.292-.059.566-.142v.535q-.274.102-.566.149-.292.054-.697.054-.744 0-1.25-.31-.5-.309-.75-.875-.25-.571-.25-1.339 0-.744.268-1.31.274-.566.804-.881.53-.322 1.28-.322.78 0 1.351.286l-.244.524q-.226-.101-.506-.184-.274-.084-.607-.084m2.756 4.423h-.601v-5.215h.601zM11.803 98.308q-.786 0-1.238.53-.453.524-.453 1.447 0 .911.417 1.446.423.53 1.268.53.321 0 .607-.053.292-.06.566-.143v.536q-.274.101-.566.148-.292.054-.696.054-.744 0-1.25-.31-.501-.309-.751-.875-.25-.571-.25-1.339 0-.744.268-1.31.274-.565.804-.881.53-.321 1.28-.321.78 0 1.351.285l-.244.524q-.226-.101-.506-.184-.274-.084-.607-.084m2.757 4.424h-.602v-5.215h.602z\" class=\"atom\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m43.789 6.839 5.022-2.9M43.789 6.839l5.022-2.9\" class=\"hi\"/\u003e\u003cpath stroke=\"#1ff01f\" d=\"m40.663 111.417-.003-5.65M15.772 99.25l5.842-3.374\" class=\"hi\"/\u003e\u003c/g\u003e\u003cg class=\"mol\"\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M74.487 57.366q-.786 0-1.238.53-.453.524-.453 1.446 0 .911.417 1.447.423.53 1.268.53.321 0 .607-.054.292-.059.566-.143v.536q-.274.101-.566.149-.292.054-.696.054-.744 0-1.25-.31-.501-.31-.751-.875-.25-.572-.25-1.34 0-.744.268-1.309.274-.566.804-.881.53-.322 1.28-.322.78 0 1.351.286l-.244.524q-.226-.101-.506-.185-.274-.083-.607-.083m2.757 4.423h-.602v-5.215h.602zM71.58 61.789h-.619v-2.286h-2.513v2.286h-.613V56.89h.613v2.071h2.513V56.89h.619z\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Title":"Sertraline hydrochloride","UNII":"UTI8907Y6X"}],"Salts":["hydrochloride"],"Solubility":"\u003e45.9 [ug/mL] (The mean of the results at pH 7.4)","StereoisomerData":[],"Stereoisomers":[],"Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 54.895 118.435\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h55v119H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"M53.833 1.038 43.789 6.839\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"M40.287 23.9h.701l1.306-11.391h-3.316z\" class=\"bond\"/\u003e\u003cpath d=\"m40.637 23.9 13.199 7.616M53.836 31.516l.005 15.239M53.841 46.755 40.647 54.38M40.647 54.38l-13.203-7.612\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m14.246 54.388 13.198-7.62M14.247 51.572l10.759-6.211\"/\u003e\u003c/g\u003e\u003cpath d=\"M14.246 54.388 1.043 46.76\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m1.038 31.511.005 15.249M3.477 32.919l.004 12.433\"/\u003e\u003c/g\u003e\u003cpath d=\"m1.038 31.511 13.198-7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m27.44 31.52-13.204-7.629M25.002 32.927l-10.766-6.22\"/\u003e\u003c/g\u003e\u003cpath d=\"M40.637 23.9 27.44 31.52M27.444 46.768 27.44 31.52\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"M40.997 54.38h-.7l-1.891 16.54 2.249-1.3 2.25 1.298z\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m40.655 69.62-13.2 7.633M40.657 72.436 29.893 78.66\"/\u003e\u003c/g\u003e\u003cpath d=\"m27.455 77.253.001 15.248\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m27.456 92.501 13.201 7.616M29.894 91.093l10.761 6.208\"/\u003e\u003c/g\u003e\u003cpath d=\"m40.657 100.117 13.2-7.634\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m53.857 92.483-.001-15.248M51.418 91.077V78.643\"/\u003e\u003c/g\u003e\u003cpath d=\"m40.655 69.62 13.201 7.615M40.657 100.117l.006 11.3M27.456 92.501 15.772 99.25\" class=\"bond\"/\u003e\u003cg fill=\"#3050f8\" stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M42.576 11.109h-.72l-2.619-4.066h-.03l.03.596q.024.357.024.732v2.738h-.566V6.21h.714l2.608 4.054h.03l-.018-.327-.024-.477q-.006-.262-.006-.482V6.21h.577zM38.133 11.109h-.619V8.823h-2.512v2.286h-.613V6.21h.613v2.072h2.512V6.21h.619z\"/\u003e\u003c/g\u003e\u003cpath fill=\"#1ff01f\" stroke=\"none\" d=\"M41.159 113.38q-.786 0-1.239.53-.452.524-.452 1.447 0 .91.417 1.446.422.53 1.268.53.321 0 .607-.054.292-.059.566-.142v.535q-.274.102-.566.149-.292.054-.697.054-.744 0-1.25-.31-.5-.309-.75-.875-.25-.571-.25-1.339 0-.744.268-1.31.274-.566.804-.881.53-.322 1.28-.322.78 0 1.351.286l-.244.524q-.226-.101-.506-.184-.274-.084-.607-.084m2.756 4.423h-.601v-5.215h.601zM11.803 98.308q-.786 0-1.238.53-.453.524-.453 1.447 0 .911.417 1.446.423.53 1.268.53.321 0 .607-.053.292-.06.566-.143v.536q-.274.101-.566.148-.292.054-.696.054-.744 0-1.25-.31-.501-.309-.751-.875-.25-.571-.25-1.339 0-.744.268-1.31.274-.565.804-.881.53-.321 1.28-.321.78 0 1.351.285l-.244.524q-.226-.101-.506-.184-.274-.084-.607-.084m2.757 4.424h-.602v-5.215h.602z\" class=\"atom\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m43.789 6.839 5.022-2.9M43.789 6.839l5.022-2.9\" class=\"hi\"/\u003e\u003cpath stroke=\"#1ff01f\" d=\"m40.663 111.417-.003-5.65M15.772 99.25l5.842-3.374\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Subjective Effects":null,"TDLo":[{"dosages":[{"amount":"2 mg/kg/2D-I","route":"oral"},{"amount":"63 mg/kg/10W-I","route":"oral"},{"amount":"70 mg/kg/7W-I","route":"oral"},{"amount":"28 mg/kg/4W-I","route":"oral"},{"amount":"10500 μg/kg/3W","route":"oral"},{"amount":"6 mg/kg/4D-I","route":"oral"}],"organism":"Human - female"},{"dosages":[{"amount":"5714 μg/kg/9D-","route":"oral"},{"amount":"3571 mg/kg/5D-","route":"oral"}],"organism":"Human - male"}],"Therapeutic Uses":"Antidepressants, especially serotonin-reuptake inhibitors, also are employed in the management of post-traumatic stress disorder, marked by anxiety, startle, painful recollection of the traumatic events, \u0026 disturbed sleep. ... The serotonin-reuptake inhibitors are agents of choice in obsessive-compulsive disorder, as well as in possibly related syndromes of impulse dyscontrol or obsessive preoccupations, including compulsive habits, bulimia (but usually not anorexia) nervosa, \u0026 body dysmorphic disorder. While their benefits may be limited, serotonin-reuptake inhibitors offer an important advance in the medical treatment of these often chronic \u0026 sometimes incapacitating disorders for which no other medical treatment, by itself, has been consistently effective, the effectiveness of pharmacological treatment of these commonly treatment-resistant disorders is greatly enhanced by use of behavioral treatments. In addition to the wide use of modern antidepressants to treat depression commonly associated with general medical illnesses, several psychosomatic disorders may respond at least partly to treatment with antidepressants of the tricyclic, MAO inhibitor, or serotonin-reuptake inhibitor types. These include chronic pain disorders, including adiabetic \u0026 other peripheral neuropathic syndromes (for which tertiaryamine tricyclics are probably superior to fluoxetine); fibromyalgia; peptic ulcer \u0026 irritable bowel syndrome; chronic fatigue; cataplexy; tics; migraine; \u0026 sleep apnea. /Antidepressants; Serotonin-reuptake inhibitors/","Title":"Sertraline","Treatment":"Treatment should consist of those general measures employed in the management of overdosage with any antidepressant. Ensure an adequate airway, oxygenation and ventilation. Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion, or in symptomatic patients. Activated charcoal should be administered. Due to large volume of distribution of this drug, forced diuresis, dialysis, hemoperfusion and exchange transfusion are unlikely to be of benefit. No specific antidotes for sertraline are known. (L1712)","UNII":"QUC7NX6WMB","Wikipedia":"Sertraline","XLogP":4.8}